Patents by Inventor George Coukos

George Coukos has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11180550
    Abstract: The invention provides compositions and methods for treating ovarian cancer. Specifically, the invention relates to administering a genetically modified T cell having ?-folate receptor (FR?) binding domain and 4-1BB (CD137) costimulatory domain to treat ovarian cancer.
    Type: Grant
    Filed: October 7, 2019
    Date of Patent: November 23, 2021
    Assignees: The Trustees of the University of Pennsylvania, Fondazione IRCCS Istituto Nazionale dei Tumori
    Inventors: Daniel J. Powell, George Coukos, Mariangela Figini, Silvana Canevari
  • Patent number: 11078285
    Abstract: The invention relates to Anti-TEM 1 antibodies or antigen-binding fragments thereof, yeast libraries comprising the same, and prophylactic, diagnostic, and therapeutic methods using the same.
    Type: Grant
    Filed: December 24, 2018
    Date of Patent: August 3, 2021
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Nathalie Scholler, Aizhi Zhao, Donald Siegel, George Coukos
  • Publication number: 20210113615
    Abstract: The invention relates to heterodimeric inactivatable chimeric antigen receptors (CARs) and their use for treatment.
    Type: Application
    Filed: April 12, 2019
    Publication date: April 22, 2021
    Applicants: Ludwig Institute for Cancer Research Ltd., École Polytechnique Fédérale de Lausanne
    Inventors: George COUKOS, Melita IRVING, Bruno CORREIA, Pablo GAINZA-CIRAUQUI, Greta Maria Paola GIORDANO ATTIANESE
  • Patent number: 10874728
    Abstract: The present invention provides methods of immunizing a subject against a tumor, inhibiting tumor growth, inhibiting tumor recurrence, treating, suppressing the growth of, or decreasing the incidence of a tumor, overcoming tolerance to a tumor vasculature marker (TVM) in a subject comprising the step of administering a vaccine comprising a TVM or a nucleic acid encoding a TVM and related vaccines. The present invention also provides a method of targeting a tumor vasculature in a subject having a tumor comprising the step of contacting said subject with a labeled compound that binds a) a tumor vasculature marker (TVM) or b) a nucleic acid molecule encoding said TVM.
    Type: Grant
    Filed: March 21, 2016
    Date of Patent: December 29, 2020
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: George Coukos, Andrea Facciabene
  • Publication number: 20200338125
    Abstract: The invention relates to a method for expanding antigen-specific lymphocytes by culturing samples from a subject containing lymphocytes or lymphocytes derived from the sample in the presence of one or more peptides comprising antigens and/or in the presence of an antigen presenting cell presenting antigens. Also disclosed is the use of such method for improving personalized immunotherapy (e.g., tumor immunotherapy).
    Type: Application
    Filed: November 6, 2018
    Publication date: October 29, 2020
    Applicant: LUDWIG INSTITUTE FOR CANCER RESEARCH LTD
    Inventors: Sara BOBISSE, Alexandre HARARI, George COUKOS
  • Publication number: 20200270341
    Abstract: The invention provides compositions and methods for treating ovarian cancer. Specifically, the invention relates to administering a genetically modified T cell having ?-folate receptor (FR?) binding domain and 4-1BB (CD137) costimulatory domain to treat ovarian cancer.
    Type: Application
    Filed: October 7, 2019
    Publication date: August 27, 2020
    Inventors: Daniel J. Powell, George Coukos, Mariangela Figini, Silvana Canevari
  • Publication number: 20200101110
    Abstract: The present invention relates to methods of designing kinase mutants for reprogramming the sensitivity of a target kinase to some specific inhibitors, methods of reprogramming the sensitivity of a target kinase to some specific inhibitors, wherein those kinase inhibitors have little or no affinity for the wild-type target kinase, vectors or cells expressing said mutated kinases, composition and uses thereof for the prevention and/or treatment of a disease or disorder, in particular cancer.
    Type: Application
    Filed: May 24, 2018
    Publication date: April 2, 2020
    Inventors: Olivier Michielin, Vincent Zoete, George Coukos, Melita Irving, Nahzli Dilek, Patrick Reichenbach, Kelly Ascencao
  • Publication number: 20190375845
    Abstract: The present invention provides methods of treating and enhancing efficacy of immunotherapy for a solid tumor in a subject, comprising the step of contacting the subject with a compound or composition that modulates the expression or activity of ETRB, ET-1, ICAM-1, or another protein found herein to play a role in homing of T cells to a solid tumor. The present invention also provides methods of prognosticating a solid tumor in a subject, comprising the step of measuring an expression level of a protein found herein to play a role in homing of T cells to a solid tumor, or a nucleotide molecule encoding same.
    Type: Application
    Filed: January 7, 2019
    Publication date: December 12, 2019
    Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Ronald J BUCKANOVICH, George COUKOS, Andrea FACCIABENE
  • Patent number: 10457729
    Abstract: The invention provides compositions and methods for treating ovarian cancer. Specifically, the invention relates to administering a genetically modified T cell having ?-folate receptor (FR?) binding domain and 4-1BB (CD137) costimulatory domain to treat ovarian cancer.
    Type: Grant
    Filed: July 18, 2016
    Date of Patent: October 29, 2019
    Assignees: The Trustees of the University of Pennsylvania, Fondazione IRCCS Istituto Nazionale dei Tumori
    Inventors: Daniel J. Powell, George Coukos, Mariangela Figini, Silvana Canevari
  • Publication number: 20190194332
    Abstract: The invention relates to Anti-TEM 1 antibodies or antigen-binding fragments thereof, yeast libraries comprising the same, and prophylactic, diagnostic, and therapeutic methods using the same.
    Type: Application
    Filed: December 24, 2018
    Publication date: June 27, 2019
    Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Nathalie Scholler, Alzhi Zhao, Donald Siegel, George Coukos
  • Patent number: 10174120
    Abstract: The present invention provides methods of treating and enhancing efficacy of immunotherapy for a solid tumor in a subject, comprising the step of contacting the subject with a compound or composition that modulates the expression or activity of ETRB, ET-1, ICAM-1, or another protein found herein to play a role in homing of T cells to a solid tumor. The present invention also provides methods of prognosticating a solid tumor in a subject, comprising the step of measuring an expression level of a protein found herein to play a role in homing of T cells to a solid tumor, or a nucleotide molecule encoding same.
    Type: Grant
    Filed: January 20, 2016
    Date of Patent: January 8, 2019
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Ronald J Buckanovich, George Coukos, Andrea Facciabene
  • Patent number: 10160809
    Abstract: The invention relates to Anti-TEM 1 antibodies or antigen-binding fragments thereof, yeast libraries comprising the same, and prophylactic, diagnostic, and therapeutic methods using the same.
    Type: Grant
    Filed: January 20, 2017
    Date of Patent: December 25, 2018
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Nathalie Scholler, Aizhi Zhao, Donald Siegel, George Coukos
  • Patent number: 9783610
    Abstract: The invention relates to variants of an antibody or antigen-binding fragment that binds specifically to an endosialin tumor endothelial marker 1 (TEM1), and prophylactic, diagnostic, and therapeutic methods using the same.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: October 10, 2017
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: George Coukos, Chunsheng Li
  • Publication number: 20170281793
    Abstract: The invention relates to Anti-TEM 1 antibodies or antigen-binding fragments thereof, yeast libraries comprising the same, and prophylactic, diagnostic, and therapeutic methods using the same.
    Type: Application
    Filed: January 20, 2017
    Publication date: October 5, 2017
    Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Nathalie SCHOLLER, Aizhi Zhao, Donald Siegel, George Coukos
  • Patent number: 9556272
    Abstract: The invention relates to Anti-TEM 1 anti-bodies or antigen-binding fragments thereof, yeast libraries comprising the same, and prophylactic, diagnostic, and therapeutic methods using the same.
    Type: Grant
    Filed: November 12, 2010
    Date of Patent: January 31, 2017
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Nathalie Scholler, Aizhi Zhao, Donald Siegel, George Coukos
  • Publication number: 20170002072
    Abstract: The invention provides compositions and methods for treating ovarian cancer. Specifically, the invention relates to administering a genetically modified T cell having ?-folate receptor (FR?) binding domain and 4-1BB (CD137) costimulatory domain to treat ovarian cancer.
    Type: Application
    Filed: July 18, 2016
    Publication date: January 5, 2017
    Inventors: Daniel J. Powell, George Coukos
  • Publication number: 20160368996
    Abstract: The present invention provides methods of treating and enhancing efficacy of immunotherapy for a solid tumor in a subject, comprising the step of contacting the subject with a compound or composition that modulates the expression or activity of ETRB, ET-1, ICAM-1, or another protein found herein to play a role in homing of T cells to a solid tumor. The present invention also provides methods of prognosticating a solid tumor in a subject, comprising the step of measuring an expression level of a protein found herein to play a role in homing of T cells to a solid tumor, or a nucleotide molecule encoding same.
    Type: Application
    Filed: January 20, 2016
    Publication date: December 22, 2016
    Inventors: RONALD J. BUCKANOVICH, GEORGE COUKOS, ANDREA FACCIABENE
  • Publication number: 20160331819
    Abstract: The present invention provides methods of immunizing a subject against a tumor, inhibiting tumor growth, inhibiting tumor recurrence, treating, suppressing the growth of, or decreasing the incidence of a tumor, overcoming tolerance to a tumor vasculature marker (TVM) in a subject comprising the step of administering a vaccine comprising a TVM or a nucleic acid encoding a TVM and related vaccines. The present invention also provides a method of targeting a tumor vasculature in a subject having a tumor comprising the step of contacting said subject with a labeled compound that binds a) a tumor vasculature marker (TVM) or b) a nucleic acid molecule encoding said TVM.
    Type: Application
    Filed: March 21, 2016
    Publication date: November 17, 2016
    Inventors: George COUKOS, Andrea Facciabene
  • Patent number: 9402865
    Abstract: The invention provides compositions and methods for treating ovarian cancer. Specifically, the invention relates to administering a genetically modified T cell having ?-folate receptor (FR?) binding domain and 4-1BB (CD137) costimulatory domain to treat ovarian cancer.
    Type: Grant
    Filed: January 18, 2012
    Date of Patent: August 2, 2016
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Daniel J. Powell, George Coukos
  • Patent number: 9289426
    Abstract: The present invention provides methods of treating and enhancing efficacy of immunotherapy for a solid tumor in a subject, comprising the step of contacting the subject with a compound or composition that modulates the expression or activity of ETRB, ET-1, ICAM-1, or another protein found herein to play a role in homing of T cells to a solid tumor. The present invention also provides methods of prognosticating a solid tumor in a subject, comprising the step of measuring an expression level of a protein found herein to play a role in homing of T cells to a solid tumor, or a nucleotide molecule encoding same.
    Type: Grant
    Filed: March 21, 2008
    Date of Patent: March 22, 2016
    Assignee: UNIVERSITY OF PENNSYLVANIA
    Inventors: Ronald J Buckanovich, George Coukos, Andrea Facciabene